Complex brain diseases seriously endanger human health, and early diagnostic biomarkers and effective treatments are currently lacking. Due to ethical constraints on human research, establishing monkey models is crucial to address these issues. With the rapid development of technology, transgenic monkey models of a range of brain diseases, especially autism spectrum disorder (ASD), have been successfully established. However, to establish practical and effective brain disease models and subsequently apply them to disease mechanism and treatment studies, there is still a lack of a standard tool, i.e., a system for collecting and analyzing the daily behaviors of brain disease model monkeys. Therefore, with the goal of undertaking a comprehensive and quantitative study of behavioral phenotypes, we established a standard daily behavior collection and analysis system, including behavioral data collection protocols and a monkey daily behavior ethogram (MDBE) for rhesus and cynomolgus monkeys, which are the most commonly used non-human primates in model construction. Then, we used ASD as an application example after referring to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), which is widely used in clinical disease diagnosis to obtain ASD core clinical symptoms. We then established a sub-ethogram (ASD monkey core behavior ethogram (MCBE-ASD)) specifically for quantitative assessment of the core clinical symptoms of an ASD monkey model based on MDBE. Subsequently, we demonstrated the high reproducibility of the system.
Animals ; Autism Spectrum Disorder ; Macaca mulatta ; Disease Models, Animal ; Behavior, Animal ; Macaca fascicularis ; Male ; Humans

Objective To analyze the plaque distribution of abdominal aorta and its branches by multislice spiral CT angiography (MSCTA).Methods 145 patients recommended to abdominal enhanced CT were randomly selected in this investigation,and divided into three groups according to their age,i.e.,young,middle and old-aged group.CTA was performed with the use of multiple planar reconstruction(MPR),volume rendering (VR)and vessel probe(VP)technology.Results 124 patients with atherosclerotic plaques of abdominal aorta and all its branch-vessels,the incidences of the three groups were 9.7%(14 cases),30.3%(44 cases)and 45.5%(66 cases)respectively(P <0.005).It showed that calcified plaques were detected in a total of 1 50 in 302 plaques of all the branch-vessels.230 plaques(76.2%)were detected in abdominal branch-vessels of grade 1,of which,the incidences of superior mesenteric artery plaques was the highest(32.4%).Of the 54 plaques(1 7.9%)detected in abdominal branch-vessels of grade 2,the incidence of splenic artery plaques was the highest(13.8%).In abdominal branch-vessels of grade 3,the plaques were mainly distributed in splen-ic lobial artery.The splenic artery plaques mainly spreaded in the middle segment,while other plaques were mostly in peristome and proximal segment of vessels.The incidences of plaques in the three branches were 47.6%(69 cases),1 5.2%(22 cases),and 9.0%(13 cases)respectively(P <0.005).Conclusion The incidences of atherosclerotic plaques are higher in the middle and aged people. The plaques of the three abdominal branch-vessels mainly distribute in the peristome and proximal segment,and are much likely to be detected in abdominal branch-vessels of grade 1.

Objective To assess the interference by calcium dobesilatein 7 peroxidase-baseduric acid assays and to determine its clinical significance.Methods In the in vitro experiments, uric acid in pooled serum with final concentrations of calcium dobesilate additions (0, 2, 4, 8, 16, 32, and 64μg/ml) were measured by 7 peroxidase-based assays.Percent Bias (%) was calculated relative to the drug-free specimen.In the in vivo experiments, changes in serum uric acid and calcium dobesilate concentrations were observed before and after calcium dobesilate administration ( baseline, 0 h, 1 h, 2 h, 3 h, 4 h, 6 h ) involunteers.The interference in different assays was assessed compared with LC-IDMS/MS method. Calcium dobesilate levels in 40 specimens from those taking calcium dobesilate were measured by HPLC method.Of the 40 specimens, 10 were selected to analyse the levels of uric acid by both peroxidase and UV measurement method to assess the impact in clinical status.Results In the in vitro study, concentrations of uric acid measured by 7 peroxidase-based assays were reduced by -6.3%to -21.2%compared with drug-free serum, when theconcentration of calcium dobesilate was16μg/ml.In the in vivo study, comparedto UA levels at 0 h, the biasesof serum uric acid determined by peroxidase method after calcium dobesilate administration(1 h, 2 h, 3 h, 4 h, 6 h) were of -3.33%, -6.79%, -7.49%, -6.07%, -4.09%, respectively.The observed uric acid concentrations for 8 participants measured by enzymatic assays were inhibited by -3.75% to -6.89% at 0 hour and by -16.9% to-22.22% at 2 hours relative to the concentrations measured by the LC-IDMS/MS method. Conclusions Calcium dobesilate produced a clinically significant negative interference with uric acid in all peroxidase-based uric acid assays,which may result in false evaluation of uric acid level in clinical status.Significant differences in the degree of interference were observed among the assays.